Lack of influence of CYP2D6 genotype on the clearance of (R)-, (S)- and racemic-methadone

International Journal of Clinical Pharmacology and Therapeutics

Volumn 45, Issue 7, 2007, Pages 410-417

  Coller, Janet K ^a   Joergensen, C ^a,b   Foster, D J R ^c   James, H ^d   Gillis, D ^d   Christrup, L ^b   Somogyi, A A ^a,d  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^d ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

CYP2D6 genotype; Methadone; Oral clearance

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; AMINE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CANNABINOID; COCAINE; CYTOCHROME P450 2D6; GENOMIC DNA; METHADONE; OPIATE DERIVATIVE;

ADULT; ARTICLE; CAUCASIAN; CHRONIC PAIN; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; GENE DUPLICATION; GENE FREQUENCY; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; METHADONE TREATMENT; OPIATE ADDICTION; PHARMACOGENETICS; PLASMA CONCENTRATION-TIME CURVE; RACEMIC MIXTURE; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; STEADY STATE; STEREOCHEMISTRY; TREATMENT DURATION;

EID: 33847686540     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP45410     Document Type: Article

References (25)

1. Bament D, Cooke R, Weekley J, Ali R. Treatment outcomes at 12 months post admission to drug treatment: the third report of the South Australian component of the Australian treatment outcomes study - Heroin. Adelaide; 2004.
2. Caplehorn JR, Dalton MS, Cluff MC, Petrenas AM. Retention in methadone maintenance and heroin addicts' risk of death. Addiction. 1994; 89: 203-209.
3. Crettol S, Deglon J-J, Besson J, Croquette-Krokkar M, Gothuey I, Hammig R, Monnat M, Huttemann H, Baumann P, Eap CB. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin Pharmacol Ther. 2005; 78: 593-604.
4. Dahl M-L, Johansson I, Bertilsson L, Ingelman-Sund-berg M, Sjöqvist F. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther. 1995; 274: 516-520.
5. Dyer KR, White J. Patterns of symptom complaints in methadone maintenance patients. Addiction. 1997; 92: 1445-1455.
6. Eap CB, Broly F, Mino A, Hammig R, Deglon JJ, Uehlinger C, Meili D, Chevalley AF, Bertschy G, Zullino D, Kosel M, Preisig M, Baumann P. Cytochrome P450 2D6 genotype and methadone steady-state concentrations. J Clin Psychopharm. 2001; 21: 229-234.
7. Farrell M, Ward J, Mattick R, Hall W, Stimson GV, des Jarlais D, Gossop M, Strang J. Methadone maintenance treatment in opiate dependence: a review. Br Med J. 1994; 309: 997-1001.
8. Foster DJR, Somogyi AA, Bochner F. Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4. Br J Clin Pharmacol. 1999; 47: 403-412.
9. Foster DJR, Somogyi AA, Dyer KR, White JM, Bochner F. Steady-state pharmacokinetics of (R)- and (S)-methadone in methadone maintenance patients. Br J Clin Pharmacol. 2000; 50: 427-440.
10. Foster DJR, Somogyi AA, White JM, Bochner F. Population pharmacokinetics of (R)-, (S)- and rac-methadone in methadone maintenance patients. Br J Clin Pharmacol. 2004; 57: 742-755.
11. Gerber JG, Rhodes JS, Gal J. Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality. 2004; 16: 36-44.
12. Griese EU, Zanger UM, Brudermanns U, Gaedigk A, Mikus G, Morike K, Stuven T, Eichelbaum M. Assessment of the predictive power of genotypes for the in vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics. 1998; 8: 15-26.
13. Iribarne C, Berthou F, Baird S, Dreano Y, Picart D, Bail JP, Beaune P, Menez JF. Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol. 1996; 9: 365-373.
14. James HM, Coller JK, Gillis D, Bahnisch J, Sallustio BC, Somogyi AA. A new simple diagnostic assay for the identification of the major CYP2D6 genotypes by DNA sequencing analysis. Int J Clin Pharmacol Ther. 2004; 42: 719-723.
15. Jarvis MA, Wu-Pong S, Kniseley JS, Schnoll SH. Alterations in methadone metabolism during late pregnancy. J Addict Dis. 1999; 18:51-61.
16. Kharasch ED, Hoffer C, Whittington D, Sheffels P. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition and miotic effects of methadone. Clin Pharmacol Ther. 2004; 76: 250-269.
17. Lötsch J, Skarke C, Wieting J, Oertel BG, Schmidt H, Brockmoller J, Geisslinger G. Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action. Clin Pharmacol Ther. 2006; 79: 72-89.
18. Lundqvist E, Johansson I, Ingelman-Sundberg M. Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes. Gene. 1999; 226: 327-338.
19. Marez D, Legrand M, Sabbagh N, Guidice J-ML, Boone P, Broly F. A novel CYP2D6 allele with an abolished splice recognition site associated with the poor metaboliser phenotype. Pharmacogenetics. 1995; 5: 305-311.
20. Marez D, Legrand M, Sabbagh N, Guidice J-ML, Spire C, Lafitte J-J, Meyer UA, Broly F. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics. 1997; 7: 193-202.
21. Plummer JL, Gourlay GK, Cherry DA, Cousins MJ. Estimation of methadone clearance: application in the management of cancer pain. Pain. 1988; 33:313-322.
22. Pond SM, Kreek MJ, Tong TG Raghunath J, Benowitz NL. Altered methadone pharmacokinetics in methadone-maintained pregnant women. J Pharmacol Exp Ther. 1985; 233: 1-6.
23. Schaeffeler E, Schwab M, Eichelbaum M, Zanger UM. CYP2D6 genotyping strategy based on gene copy number determined by TaqMan real-time PCR. Hum Mutat. 2003; 22: 476-485.
24. Tateishi T, Chida M, Ariyoshi N, Mizorogi Y, Kamataki T, Kobayashi K. Analysis of the CYP2D6 gene in relation to dextromethorphan O-demethylation capacity in a Japanese population. Clin Pharmacol Ther. 1999; 65: 570-575.
25. Wang J-S, DeVane CL. Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro. Drug Metab Dispos. 2003; 31: 742-747.